Navigation Links
OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.
Date:10/28/2008

VANCOUVER, British Columbia, Oct. 28 /PRNewswire-FirstCall/ -- ProtoKinetix Inc. (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that OTC Financial Network (OTCFN), a division of National Financial Communications Corp. (NFC), has issued a corporate profile on the Company. The OTCFN Report includes details on the ProtoKinetix technology platform, its multiple commercial applications, global target markets and management team. Interested parties can download the report at http://www.otcfn.com/pktx/pktx-report.pdf.

"Dr. Castelot-Deliencourt, chief scientist for ProtoKinetix, has achieved what was previously thought to be the impossible. She created a synthetic version of AFGP (Anti-Freeze Glycoprotein), a naturally occurring compound that enables cell survival in freezing temperatures. Her lab-created version is the industry's first stable, non-toxic and bioactive compound, even at low concentrations. Patented and trademarked by ProtoKinetix as AAGPs(TM), this revolutionary technology and its derivatives have shown to increase cellular health, survival and seem to have anti-inflammatory properties," said Geoffrey Eiten, publisher of the OTCFN Report.

"This year, ProtoKinetix entered its exciting commercial development phase, establishing partnerships with skin care manufacturers, and umbilical cord blood and health care companies to research and develop life-enhancing applications of AAGP(TM). The Company's goal is to begin generating recurring licensing revenues and royalty fees in 2009, and to increase shareholder value over the long-term," concluded Eiten.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the Company about the broad range of applications for AAGP(TM) products. For more information, visit http://www.protokinetix.com.

OTC Financial Network serves as special advisor to ProtoKinetix Inc. and has received fees for services, including two hundred and fifty-thousand shares of restricted stock, in addition to an option to purchase two-hundred fifty-thousand shares at an exercise price of twenty cents per share, for the creation and implementation of an awareness program, including the OTC FN Report. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. A full disclaimer can be found online by visiting http://www.otcfn.com/pktx/disclaimer.html.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

CONTACT

At OTC Financial Network:

Rick McCaffrey, Investor Relations

781-444-6100 x625

rick@otcfn.com

http://www.otcfn.com/pktx

At ProtoKinetix:

Blair Henderson

604-687-9887

Email: info@protokinetix.com


'/>"/>
SOURCE ProtoKinetix Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
2. Avicena Group to Present at Noble Financial Conference
3. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Avitar Reports Third Quarter Financial Results for Fiscal 2007
7. Response Genetics Reports Second Quarter 2007 Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
10. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Recent ... cell type. Many treatments for specific cancers, such as breast, prostate, or lung, ... is androgen deprivation therapy for advanced prostate cancer. , This therapy limits ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar ... has secured $2M in funding from an impressive group of investors, including Rev1 ... Thrive Fund. With this investment, 3Bar is broadening availability of its groundbreaking offering ...
(Date:8/16/2017)... edition of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ... list for the third year in a row. Now in its 36th ... a set of quantitative metrics. In addition, BioPoint was also named to ... Bay State . ... ...
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past ... support with crowdsourced data collection, GeneFo now offers this platform to ... aligning and amplifying support, adherence, and data collection vis a vis ... foundations mark the successful launch of this offer. ... GeneFo ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):